Epidemiologist

Epidemiologist
Epidemiologists help with study design, collection and statistical analysis of data, and interpretation and dissemination of results (including peer review and occasional systematic review). Epidemiology has helped develop methodology used in clinical research, public health studies and, to a lesser extent, basic research in the biological sciences
Tampilkan postingan dengan label HIV. Tampilkan semua postingan
Tampilkan postingan dengan label HIV. Tampilkan semua postingan

Senin, 09 Desember 2013

Conditional economic incentives for reducing HIV risk behaviors: integration of psychology and behavioral economics

Conditional economic incentives for reducing HIV risk behaviors: integration of psychology and behavioral economics.

Source

Department of Behavioral and Social Sciences, Brown University, Providence, RI 02906, USA. Don_Operario@brown.edu

Abstract

OBJECTIVE:

This article reviews psychology and behavioral economic approaches to HIV prevention, and examines the integration and application of these approaches in conditional economic incentive (CEI) programs for reducing HIV risk behavior.

METHODS:

We discuss the history of HIV prevention approaches, highlighting the important insights and limitations of psychological theories. We provide an overview of the theoretical tenets of behavioral economics that are relevant to HIV prevention, and utilize CEIs as an illustrative example of how traditional psychological theories and behavioral economics can be combined into new approaches for HIV prevention.

RESULTS:

Behavioral economic interventions can complement psychological frameworks for reducing HIV risk by introducing unique theoretical understandings about the conditions under which risky decisions are amenable to intervention. Findings from illustrative CEI programs show mixed but generally promising effects of economic interventions on HIV and sexually transmitted infection (STI) prevalence, HIV testing, HIV medication adherence, and drug use.

CONCLUSIONS:

CEI programs can complement psychological interventions for HIV prevention and behavioral risk reduction. To maximize program effectiveness, CEI programs must be designed according to contextual and population-specific factors that may determine intervention applicability and success.
PsycINFO Database Record (c) 2013 APA, all rights reserved.

Senin, 18 November 2013

RESISTANSI TERHADAP OBAT

Apa Resistansi Itu?
HIV dianggap ‘resistan (kebal)’ terhadap obat antiretroviral (ARV) tertentu bila virus itu terus menggandakan diri (bereplikasi) walaupun kita memakai obat tersebut. Waktu HIV bereplikasi, sering kali hasilnya tidak persis sama dengan aslinya – ada sedikit perubahan. Sebagian virus yang dibuat ini, yang disebut mutan, dapat menyebabkan resistansi. Tipe virus yang ‘liar’ adalah bentuk HIV yang paling umum. Virus yang berbeda dari tipe liar dianggap mutan.
ARV tidak mampu mengendalikan virus yang resistan terhadapnya. Virus yang resistan dapat kebal terhadap obat tersebut. Jika kita tetap memakai obat itu, virus yang resistan akan bereplikasi lebih cepat dibanding virus liar. Ini disebut ‘tekanan pilihan’, dengan akibat virus yang resistan akan berkuasa.
Bila kita berhenti memakai ARV, tidak ada tekanan pilihan. Virus tipe liar (asli) akan bereplikasi lebih cepat dibanding virus yang resistan. Namun virus yang resistan masih tersembunyi dalam sel di luar aliran darah, misalnya di kelenjar getah bening, dan akan cepat muncul kembali jika kita mulai kembali memakai obat yang sama.
Tes resistansi membantu dokter untuk memberi informasi tepat pada pasien agar pasien dapat mengambil keputusan terbaik tentang pengobatan.
Bagaimana Resistansi Berkembang?
HIV biasanya menjadi resistan waktu virus tidak dikendali secara keseluruhan oleh obat yang kita pakai. Namun, bisa jadi kita tertular dengan HIV yang sudah resistan terhadap satu atau lebih ARV.
Semakin cepat HIV bereplikasi, semakin banyak mutan muncul. Mutasi terjadi secara tidak sengaja. HIV tidak ‘mengetahui’ mutasi mana yang akan kebal terhadap obat.
HIV dapat menjadi resistan terhadap beberapa jenis obat akibat hanya satu mutasi. Ini benar dengan 3TC dan obat golongan NNRTI. Dari sisi lain, untuk mengembangkan resistansi pada beberapa obat lain, termasuk kebanyakan obat golongan protease inhibitor (PI), HIV harus melalui serangkaian mutasi.
Cara terbaik untuk mencegah resistansi adalah untuk mengendalikan HIV dengan memakai ARV yang manjur. Bila kita melupakan dosis obat, HIV akan lebih mudah bereplikasi. Makin banyak mutan akan muncul. Beberapa di antaranya dapat menyebabkan resistansi.
Bila kita harus berhenti memakai ARV apa pun, bicara dengan dokter. Kita mungkin harus berhenti memakai satu jenis obat sebelum berhenti yang lain. Jika kita berhenti memakai ARV dengan cara yang benar waktu virus dikendalikan, kemungkinan kita dapat mulai memakainya lagi kemudian tanpa masalah.
Cara Resistansi Dipastikan
Ada tiga cara untuk mengetahui bahwa resistansi sudah muncul:
  • Cara klinis: Mengamati tanda/gejala bahwa HIV tetap menggandakan diri dalam tubuh kita walaupun kita memakai ARV.
  • Cara fenotipe: Melihat apakah HIV tetap menggandakan diri dalam tabung reaksi setelah ARV diberikan.
  • Cara genotipe: Mencari kode genetik HIV mempunyai mutasi yang terkait dengan resistansi terhadap obat.
Resistansi klinis dapat dilihat dalam peningkatan pada viral load, penurunan jumlah CD4, berat badan menurun, dan kejadian baru atau kambuhan infeksi oportunistik. Tes laboratorium dibutuhkan untuk mengukur resistansi fenotipe dan genotipe.
Tes Resistansi
Ada tiga jenis tes resistansi:
  • Tes fenotipe: Contoh HIV dibiakkan dalam laboratorium. Kemudian satu jenis ARV diberikan. Kecepatan pertumbuhan virus dibandingkan dengan virus liar. Jika HIV dalam contoh bereplikasi lebih cepat, maka virus tersebut dianggap resistan pada obat yang bersangkutan. Tes fenotipe lebih terpilih untuk orang dengan resistansi yang diketahui atau dicurigai, terutama terhadap PI.
  • Tes genotipe: Kode genetik virus dalam contoh dibaca untuk menentukan apakah ada mutasi tertentu yang diketahui menimbulkan resistansi terhadap ARV apa pun. Tes genotipe lebih terpilih untuk orang yang mengalami masalah dengan rejimen terapi ARV (ART) lini pertama atau kedua.
  • Tes fenotipe virtual: Sebetulnya tes ini adalah cara menafsirkan hasil tes genotipe. Tes ini lebih cepat dan murah dibandingkan tes fenotipe.
Resistansi Silang
Kadang kala, jika virus kita mengembangkan resistansi terhadap satu macam obat, virus juga menjadi resistan terhadap ARV lain. Ini disebut ‘resistansi silang’ atau ‘cross resistance’ terhadap obat atau golongan obat lain. Misalnya, sebagian besar HIV yang resistan terhadap efavirenz (sejenis NNRTI) juga resistan terhadap nevirapine (sejenis NNRTI lain) dan sebaliknya.
Resistansi silang adalah penting bila kita harus mengganti ARV akibat kegagalan terapi karena resistansi. Kita harus memilih obat baru yang tidak resistan silang dengan obat yang kita pernah pakai.
Ilmuwan belum sepenuhnya memahami resistansi silang. Namun banyak jenis ARV sedikitnya sebagian resistan silang. Sebagaimana HIV mengembangkan lebih banyak mutasi, virus menjadi lebih sulit dikendalikan. Pakai semua dosis ARV persis sesuai dengan anjuran. Ini mengurangi risiko resistansi dan resistansi silang, dan juga mencadangkan lebih banyak pilihan jika kita harus menggantikan ARV pada masa depan.
Masalah dengan Tes Resistansi
Tes resistansi belum tersedia di Indonesia. Harganya di negara maju masih sangat mahal.
Tes ini kurang mampu mendeteksi mutan minoritas (di bawah 20% dari virus keseluruhan). Juga, tes resistansi lebih mampu bila viral load lumayan tinggi. Bila viral load kita sangat rendah, tes mungkin tidak berhasil. Tes biasanya tidak dapat dilakukan bila viral load kita di bawah 500-1.000.
Hasil tes resistansi dapat sulit ditafsirkan. Kadang kala hasil tes tidak menjelaskan apa yang sebenarnya terjadi. Obat yang menurut tes seharusnya berhasil ternyata tidak, dan sebaliknya. Kadang-kadang tes fenotipe dan genotipe memberi hasil yang bertentangan. Beberapa mutasi dapat mengurangi keganasan HIV atau menyebabkan HIV menjadi lebih rentan terhadap obat tertentu lain.
Penelitian baru-baru ini memberi kesan bahwa tes resistansi genotipe sebaiknya dilakukan pada semua pasien sebelum mereka mulai ART. Hal ini dapat menghemat biaya karena pasien tidak diberi obat yang tidak efektif akibat virusnya sudah resistan terhadap obat tersebut.
Tes resistansi tidak dibutuhkan untuk memastikan apakah ART kita gagal; kegagalan lebih baik dipastikan dengan tes viral load (lihat Lembaran Informasi 125). Tes resistansi mungkin bermanfaat untuk memastikan rejimen terbaik untuk mengganti rejimen yang diketahui gagal.

TERAPI ANTIRETROVIRAL (ART)



Apa Terapi Antiretroviral Itu?
Terapi antiretroviral (ART) berarti mengobati infeksi HIV dengan beberapa obat. Karena HIV adalah retrovirus, obat ini biasa disebut sebagai obat antiretroviral (ARV). ARV tidak membunuhvirus itu. Namun, ART dapat melambatkan pertumbuhan virus. Waktu pertumbuhan virus dilambatkan, begitu juga penyakit HIV.
Apa Siklus Hidup HIV Itu?
Ada beberapa langkah dalam siklus hidup HIV (lihat Lembaran Informasi (LI) 400 untuk gambar):
  1. Virus bebas beredar dalam aliran darah
  2. HIV mengikatkan diri pada sel
  3. HIV menembus sel dan mengosongkan isinya dalam sel
  4. Kode genetik HIV diubah dari bentuk RNA menjadi bentuk DNA dengan bantuan olehenzim reverse transcriptase
  5. DNA HIV dipadukan dengan DNA sel dengan bantuan oleh enzim integrase. Dengan pemaduan ini, sel tersebut menjadi terinfeksi HIV.
  6. Waktu sel yang terinfeksi menggandakan diri, DNA HIV diaktifkan, dan membuat bahan baku untuk virus baru
  7. Semua bahan yang dibutuhkan untuk membuat virus baru dikumpulkan
  8. Virus yang belum matang mendesak ke luar sel yang terinfeksi dengan proses yang disebut ‘budding (tonjolan)’
  9. Jutaan virus yang belum matang dilepas dari sel yang terinfeksi
  10. Virus baru menjadi matang: bahan baku dipotong oleh enzim protease dan dirakit menjadi virus yang siap bekerja
ARV yang Disetujui di AS
Setiap tipe atau ‘golongan’ ARV menyerang HIV dengan cara berbeda. Saat ini ada limagolongan obat disetujui di AS.
Golongan obat anti-HIV pertama adalah nucleoside reverse transcriptase inhibitor atau NRTI, juga disebut analog nukleosida. Obat golongan ini menghambat langkah keempat di atas, yaitu perubahan bahan genetik HIV dari bentuk RNA menjadi bentuk DNA yang dibutuhkan dalam langkah berikut. Obat dalam golongan ini yang disetujui di AS dan masih dibuat adalah:
  • 3TC (lamivudine)
  • Abacavir (ABC)
  • AZT (ZDV, zidovudine)
  • d4T (stavudine)
  • ddI (didanosine)
  • Emtricitabine (FTC)
  • Tenofovir (TDF; analog nukleotida)
Golongan obat kedua menghambat langkah yang sama dalam siklus hidup HIV, tetapi dengan cara lain. Obat ini disebut non-nucleoside reverse transcriptase inhibitor atau NNRTI. Lima NNRTI disetujui di AS:
  • Delavirdine (DLV)
  • Efavirenz (EFV)
  • Etravirine (ETV)
  • Nevirapine (NVP)
  • Rilpivirine (RPV)
Golongan ketiga ARV adalah protease inhibitor (PI). Obat golongan ini menghambat langkah kesepuluh, dengan bahan virus baru dipotong sesuai untuk membuat virus baru. Sembilan PI disetujui dan masih dibuat di AS:
  • Atazanavir (ATV)
  • Darunavir (DRV)
  • Fosamprenavir (FPV)
  • Indinavir (IDV)
  • Lopinavir (LPV)
  • Nelfinavir (NFV)
  • Ritonavir (RTV)
  • Saquinavir (SQV)
  • Tipranavir (TPV)
Golongan ARV keempat adalah fusion inhibitor. Obat golongan ini mencegah pengikatan HIV pada sel dengan menghambat langkah kedua dari siklus hidupnya. Dua obat golongan ini sudah disetujui di AS:
  • Enfuvirtide (T-20)
  • Maraviroc (MVC)
Golongan ARV terbaru adalah integrase inhibitor (INI). Obat golongan ini mencegah pemaduan kode genetik HIV dengan kode genetik sel dengan menghambat langkah kelima dari siklus hidupnya. Sudah tersedia dua obat INI:
  • Raltegravir (RGV)
  • Elvitegravir (EGV)
Namun elvitegravir hanya disetujui sebagai kandungan dalam Striblid, pil kombinasi dengan cobicistat, emtricitabine dan tenofovir.
Bagaimana Obat Ini Dipakai?
Obat ARV umumnya dipakai dalam gabungan dengan tiga atau lebih ARV dari lebih dari satu golongan. Hal ini disebut sebagai terapi kombinasi, atau ART. ART bekerja jauh lebih baik daripada hanya satu ARV sendiri. Cara penggunaan obat ini mencegah munculnya resistansi.
Produsen ARV terus-menerus berupaya untuk membuat obatnya lebih mudah dipakai, dan sudah menggabung dua atau lebih jenis obat dalam satu pil.
Apa Resistansi terhadap Obat Itu?
Waktu HIV menggandakan diri, sebagian dari bibit HIV baru dapat menjadi sedikit berbeda dengan aslinya. Jenis berbeda ini disebut mutan. Kebanyakan mutan langsung mati, tetapi beberapa di antaranya terus menggandakan diri, walaupun kita tetap memakai ART – mutan tersebut ternyata kebal terhadap obat. Jika ini terjadi, obat tidak bekerja lagi. Hal ini disebut sebagai ‘mengembangkan resistansi’ terhadap obat tersebut. Lihat LI 126 untuk informasi lebih lanjut tentang resistansi.
Jika hanya satu jenis ARV dipakai, virus secara mudah mengembangkan resistansi terhadapnya. Oleh karena itu, penggunaan hanya satu jenis ARV (yang disebut monoterapi) tidak dianjurkan. Tetapi jika dua jenis obat dipakai, virus mutan harus unggul terhadap dua obat ini sekaligus. Dan jika tiga jenis obat dipakai, kemungkinan munculnya mutan yang dapat sekaligus unggul terhadap semuanya sangat kecil. Penggunaan kombinasi tiga jenis ARV berarti membutuhkan jauh lebih lama untuk mengembangkan resistansi.
Apakah Obat Ini Dapat Menyembuhkan AIDS?
Saat ini, belum ditemukan penyembuh infeksi HIV. ARV mengurangi viral load, yaitu jumlah HIV dalam aliran darah kita. Kalau viral load kita lebih rendah, kita tetap sehat lebih lama. Kita juga kurang mungkin menularkan HIV pada orang lain. Lihat LI 125 untuk informasi lebih lanjut tentang tes viral load.
Viral load beberapa orang menjadi begitu rendah sehingga tidak dapat diukur oleh tes viral load; viral loadnya disebut ‘tidak terdeteksi’. Ini bukan berarti virus hilang, dan tidak berarti orang tersebut ‘sembuh’.
Kapan Sebaiknya Kita Mulai?
Belum ada jawaban yang jelas untuk pertanyaan ini. Sebagian besar dokter akan mempertimbangkan jumlah CD4, dan gejala yang kita alami. Menurut pedoman WHO, ART sebaiknya dimulai sebelum CD4 turun di bawah 350, bila kita hamil, kita alami TB aktif, kita membutuhkan terapi untuk virus hepatitis B (HBV), atau kita mempunyai gejala penyakit terkait HIV yang sedang atau berat. Kriteria untuk mulai ditentukan dalam pedoman nasional (lihatLI 404). Keputusan untuk memulai ART sangat penting, dan sebaiknya dibahas dahulu dengan dokter. Untuk informasi lebih lanjut mengenai mulai ART, lihat buku kecil Yayasan Spiritia “Pengobatan untuk AIDS: Ingin Mulai?”
Obat Apa yang Sebaiknya Kita Pakai?
Setiap ARV, sama seperti semua obat lain, menimbulkan efek samping (lihat LI 550). Beberapa efek samping ini gawat. Lihat Lembaran Informasi untuk masing-masing obat. Beberapa kombinasi lebih mudah ditahan dibandingkan dengan kombinasi lain, dan beberapa di antaranya tampak lebih berhasil. Setiap orang berbeda, dan kita, bersama dengan dokter, harus memutuskan obat apa yang kita pilih.
Tes viral load dipakai untuk menentukan apakah ART bekerja sebagaimana mestinya. Bila viral load kita tidak turun, atau turun tetapi naik kembali, mungkin kita harus beralih ke kombinasi ARV lain.
Apa yang Selanjutnya?
Obat baru sedang ditelitikan dalam kelima golongan yang ada. Para peneliti juga berupaya mengembangkan golongan obat baru, misalnya obat yang menghambat langkah lain pada siklus hidup HIV, dan obat yang akan menguatkan ketahanan oleh kekebalan tubuh.

Senin, 04 November 2013

Vital Signs: HIV Prevention Through Care and Treatment — United States

Abstract

Background: An estimated 1.2 million persons in the United States were living with human immunodeficiency virus (HIV) infection in 2008. Improving survival of persons with HIV and reducing transmission involve a continuum of services that includes diagnosis (HIV testing), linkage to and retention in HIV medical care, and ongoing HIV prevention interventions, including appropriately timed antiretroviral therapy (ART).
Methods: CDC used three surveillance datasets to estimate recent HIV testing and HIV prevalence among U.S. adults by state, and the percentages of HIV-infected adults receiving HIV care for whom ART was prescribed, who achieved viral suppression, and who received prevention counseling from health-care providers. Published data were used to estimate the numbers of persons in the United States living with and diagnosed with HIV and, based on viral load and CD4 laboratory reports, linked to and retained in HIV care.
Results: In 2010, 9.6% of adults had been tested for HIV during the preceding 12 months (range by state: 4.9%–29.8%). Of the estimated 942,000 persons with HIV who were aware of their infection, approximately 77% were linked to care, and 51% remained in care. Among HIV-infected adults in care, 45% received prevention counseling, and 89% were prescribed ART, of whom 77% had viral suppression. Thus, an estimated 28% of all HIV-infected persons in the United States have a suppressed viral load.
Conclusions: Prevalence of HIV testing and linkage to care are high but warrant continued effort. Increasing the percentages of HIV-infected persons who remain in HIV care, achieve viral suppression, and receive prevention counseling requires additional effort.
Implications for Public Health Practice: Public health officials and HIV care providers should improve engagement at each step in the continuum of HIV care and monitor progress in every community using laboratory reports of viral load and CD4 test results.
Introduction
Human immunodeficiency virus (HIV) causes a chronic infection that leads to a progressive disease. Without treatment, most persons with HIV develop acquired immunodeficiency syndrome (AIDS) within 10 years of infection, which results in substantial morbidity and premature death (1). Approximately 50,000 persons in the United States were infected with HIV annually during 2006–2009 (2). Approximately 16,000 persons with AIDS die each year (3). A consistently suppressed HIV viral load is associated with reduced morbidity and mortality and a lower probability of transmitting HIV to sex partners (4). Testing identifies infected persons and is the entry point to a continuum of HIV health-care and social services that improve health outcomes, including survival. This continuum includes diagnosis (HIV testing), linkage to and retention in continuous medical care for HIV, prevention counseling and other services that reduce transmission, and appropriately timed and consistent antiretroviral therapy (ART) for viral suppression. This report estimates the number of HIV-infected persons who received selected services along the continuum of HIV care in the United States and the overall percentage of persons with HIV who had a suppressed viral load.
Methods
Data reported through June 2010 to the National HIV Surveillance System were used to calculate rates* by state per 100,000 population among persons aged 18–64 years living with diagnosed HIV infection (prevalence) at the end of 2008. Behavioral Risk Factor Surveillance System data from 2010 were used to estimate percentages by state of persons aged 18–64 years who reported testing for HIV during the 12 months preceding the interview. Medical Monitoring Project (MMP)§ data were used to estimate numbers and nationally representative percentages of adults aged ≥18 years receiving medical care who reported receiving prevention counseling in a clinical setting during the 12 months preceding the interview, and whose medical record documented that they 1) were prescribed ART during the 12 months preceding the interview and 2) had a suppressed viral load (defined as ≤200 copies/mL) at their most recent test.
Using these surveillance data and published information, CDC assessed the estimated number of persons with HIV infection (7) and the numbers and percentages of persons who were 1) aware of their infection (7), 2) linked to care (8,9), 3) retained in care (8–11), 4) prescribed ART, and 5) virally suppressed. From these analyses, CDC developed a national estimate of the percentage of all HIV-infected persons with viral suppression.
Results
In 2008, an estimated 1.2 million persons were living with HIV in the United States, of whom 80% had been diagnosed (7). The prevalence rate for persons aged 18–64 years with an HIV diagnosis ranged by state from 40.1 to 3,365.2 per 100,000 population (Figure 1). In 2010, an estimated 9.6% of persons aged 18–64 years reported recent HIV testing (range by state: 4.9%–29.8%) (Figure 2). In general, recent HIV testing percentages were higher in states with higher HIV prevalence rates.
According to published studies, approximately 77% of persons diagnosed with HIV were linked to care within 3–4 months of diagnosis (8,9), and 51% were retained in ongoing care (8–11). Among adults aged ≥18 years in MMP representing persons receiving HIV medical care, 89% had been prescribed ART. Of these, 77% had a suppressed viral load at their most recent test (Table). CDC synthesized these findings to determine the number of persons in selected categories of the continuum of HIV care (Figure 3), and estimated that 328,475 (35%) of 941,950 persons diagnosed with HIV (or 28% of all 1,178,350 persons with HIV) in the United States are virally suppressed.
The percentages of patients in MMP who were prescribed ART, had documented viral suppression, and received prevention counseling from a health-care provider during the preceding 12 months varied by age group, race/ethnicity, and reported sexual behavior (Table). Prescription of ART ranged from 76% for patients aged 18–24 years to 92% for those aged ≥55 years; of those prescribed ART, viral suppression was lowest among patients aged 25–34 years (69%) and highest in those aged ≥55 years (85%). Among the 92% of whites, 89% of Hispanics or Latinos, and 86% of blacks or African Americans who were prescribed ART, 84% of whites and 79% of Hispanics or Latinos had documented viral suppression, compared with 70% of blacks or African Americans. ART prescriptions were documented for 91% of men who have sex with women only (MSW), 89% of men who have sex with men (MSM), and 86% of women who have sex with men (WSM). By sex, 79% of males (81% of MSM and 75% of MSW) had viral suppression, compared with 71% of females.
Among persons in MMP, 45% had received prevention counseling during the preceding year, ranging from 36% among persons aged ≥55 years to 73% among persons aged 18–24 years. By race/ethnicity, 54% of blacks or African Americans and 52% of Hispanics or Latinos received prevention counseling, compared with 29% of whites. Prevention counseling was received by 50% of MSW and WSM, but only 39% of MSM.
Conclusions and Comment
Among MMP participants (representing adults aged ≥18 years receiving medical care for HIV infection), 89% had been prescribed ART, of whom 77% had a suppressed viral load. However, only 28% of all persons living with HIV infection in the United States are estimated to be virally suppressed, in large part because only approximately 41% are both aware of their infection and receiving ongoing HIV care.
The observed higher percentages of persons who were recently tested in areas with higher HIV prevalence are encouraging. These findings are consistent with the recommendations of the 2010 National HIV/AIDS Strategy to intensify efforts in communities where HIV is concentrated most heavily, but continued effort is necessary to achieve the goal of increasing the proportion of persons aware of their infection from 80% to 90% (12). CDC's comprehensive HIV testing strategy includes 1) routine HIV screening in health-care settings with prevalence of undiagnosed infection ≥0.1%, 2) targeted testing of persons with risk factors associated with increased HIV prevalence, and 3) retesting at least annually for HIV-negative persons at increased risk for HIV (13).
Although the percentage of persons with HIV who are linked to care after diagnosis is 77%, more effort is needed to ensure that those patients remain in care and to eliminate disparities among subgroups who are prescribed ART and subsequently achieve viral suppression. In MMP, compared with whites, smaller percentages of blacks or African Americans and Hispanics or Latinos were prescribed ART and were virally suppressed. Differences in rates of ART prescription and viral suppression might reflect differences in insurance coverage, prescription drug costs, health-care providers' perceptions of patients' probability of adherence, or other factors associated with adherence.
Ongoing prevention interventions for persons with HIV infection are key components to reduce HIV transmission. Prevention counseling is recommended as an ongoing part of HIV care for all patients (14), but fewer than half of patients in MMP had received prevention counseling from their health-care provider during the preceding year. These low percentages, especially among MSM, who account for the most new HIV infections in the United States (2), indicate a need for health-care providers to deliver HIV prevention services more consistently.
The findings in this report are subject to at least two limitations. First, documentation of a recent suppressed viral load might not be indicative of consistent viral suppression. Second, the percentage of persons with viral suppression might be overestimated or underestimated and not representative of all persons with HIV in the United States because 1) not all states have implemented routine reporting of CD4 and viral load test results, so estimates of percentages of persons retained in care are based on a limited number of states; 2) MMP data might include persons more likely to be retained in care or adhere to ART; and 3) the estimate assumed no viral suppression among persons not in care, although a small percentage of persons demonstrate viral suppression without taking ART.
CDC's estimate that 28% of all HIV-infected persons are virally suppressed is higher than the 19% reported in a recent review (15). CDC used more recent data and different methods that did not depend on estimates of the proportion of persons in care who need ART. The previous estimate calculated that 80% of persons in care need ART, of whom 75% receive it (15).
The 2010 National HIV/AIDS Strategy goals of reducing HIV incidence, increasing access to care and improving health outcomes for persons living with HIV, and reducing HIV-related disparities and health inequities are interdependent. Reducing national HIV incidence and improving individual health outcomes require increased access to care and elimination of disparities in the quality of care received. To meet these goals and break the cycle of HIV transmission in the United States, achieving high levels of engagement at every stage in the continuum of care is essential. Currently, a substantial proportion of HIV-infected persons have been tested and initially linked to care, and of those retained in care, 89% are prescribed ART, and 77% achieve viral suppression. However, only an estimated 28% of all HIV-infected persons in the United States are virally suppressed, largely because even among those with diagnosed infection, only 51% are receiving regular HIV care (8–11). Without substantial improvement in these percentages, 1.2 million new HIV infections would be expected to occur in the United States over the next 20 years (16). Based on estimated lifetime HIV treatment costs of $367,000 per person (2009 dollars) (17) caring for persons who become infected could cost as much as $450 billion in health-care expenditures (16).
CDC supports state and local health department programs to expand and monitor HIV testing and linkage to medical care, especially in high prevalence areas. Because ensuring that persons with HIV infection receive continuous medical care is important, CDC is working with health departments throughout the nation to expand their efforts to collect laboratory reports on all CD4 and viral load test results for persons diagnosed with HIV. Local programs can use these data (in accordance with privacy and confidentiality policies, laws, and regulations) to identify persons not in care and to facilitate efforts to ensure they receive appropriate care. CDC will continue using MMP to monitor receipt of ART and prevention services among persons in care and identify opportunities for improvement. CDC will share this information with grantees, partners, health-care providers, and other federal agencies (e.g., the Health Resources and Services Administration) to improve the delivery of care, treatment, and prevention services for all persons with HIV infection.
The results in this report indicate that progress has been made; however, continued and intensified efforts are needed. Only with success at each step in the continuum of HIV care (i.e., identifying those with HIV, linking them to and retaining them in care, and ensuring they receive optimal treatment and prevention services) can the ultimate goals of improving health, extending lives, and preventing further HIV transmission be achieved.

Reported by

Stacy M. Cohen, MPH, Michelle M. Van Handel, MPH, Bernard M. Branson, MD, Janet M. Blair, PhD, H. Irene Hall, PhD, Xiaohong Hu, MS, Linda J. Koenig, PhD, Jacek Skarbinski, MD, Angie Tracey, Jonathan Mermin, MD, Linda A. Valleroy, PhD, Div of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. Corresponding contributor: Stacy M. Cohen, scohen@cdc.gov, 404-639-4493.

Antiretroviral therapy

Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering when use is made of a potent ARV regimen, particularly in early stages of the disease. Furthermore, expanded access to ART can also reduce the HIV transmission at population level, impact orphan hood and preserve families.

Antiretroviral therapy

Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering when use is made of a potent ARV regimen, particularly in early stages of the disease.
Furthermore, expanded access to ART can also reduce the HIV transmission at population level, impact orphanhood and preserve families.
In 2011, an estimated 34 million people were living with HIV.
WHO and UNAIDS estimate that at least 15 million people were in need of antiretroviral therapy in 2011. As of the end of 2012, 9.7 million people had access to ART in low- and middle-income countries. WHO is providing countries with ongoing guidance, tools and support in delivering and scaling up ART within a public health approach.
In 2010, WHO and UNAIDS launched the Treatment 2.0 strategy, which promotes radical simplification of ART, with accelerated treatment scale-up and full integration with prevention, in order to reach Universal Access.
WHO launched in July 2013 new guidelines with recommendations on ART for adults and adolescents.

Acquired Immune Deficiency Syndrome (AIDS)

The human immunodeficiency virus (HIV) which causes acquired immune deficiency syndrome (AIDS) has brought about a global epidemic of massive proportions. HIV is a retrovirus and also the term often applied to the infection before the deterioration of the immune system to produce a full-blown picture of AIDS.

Worldwide

It has become a massive problem and according to the World Health Organization in 2008:[1]
  • An estimated 33.4 million people are living with HIV worldwide. 2006 figures were 38.6 million.
  • There were 2.7 million newly infected people in 2008. 2006 figures were 4.1 million.
  • 2.0 million people died of AIDS in 2008. 2006 figures were 2.8 million.
Poor record keeping and returns from some countries make these figures unreliable.

In Africa antiretroviral treatment coverage has also increased:[1]
  • In 2003 in Sub-Saharan Africa, approximately 100,000 people were receiving treatment; 2% of those needing it.
  • In 2008 2,120,000 people were receiving treatment; 30% of those needing it.
  • The percentage of pregnant women receiving antiretrovirals for preventing mother-to-child transmission of HIV in Sub-Saharan Africa increased from 15% in 2005 to 45% in 2008.
  • The median percentage of people 15-49 years old who know their HIV status, through an HIV test in Sub-Saharan Africa, was 22%. High and low respectively Sierra Leone 100%, Ghana 7%.
  • The percentage of children under 18 years old who have lost one or both parents, in countries with HIV prevalence greater than 1 percent, is 28% in Lesotho, 24% in Zimbabwe and 21% in Swaziland (3 highest).
While this progress is notable, the HIV prevention response falls short in many areas. The response to the problem of AIDS varies considerably between countries, irrespective of risk. Some are just slow to take the matter seriously whilst others are still denying that it is a problem in their country. In many parts of Africa the prevalence appears to be getting stable. This means that the number of people dying from the disease is roughly equal to the number of new cases.

According to a report from the Health Protection Agency (HPA), there were an estimated 83,000 adults aged over 15 with HIV in the UK in 2008, 27% of whom were unaware of their infection.[2] The number of deaths among HIV-infected people has remained stable over the past decade, and a total of 525 people (387 men and 138 women) infected with HIV were reported to have died in 2008. There were 7,298 new diagnoses in 2008 in the UK. This represents a slight decline on previous years, predominantly due to fewer diagnoses among young people who acquired their infection abroad.United Kingdom


Within the UK the HPA Centre for Infections receives information on HIV infections from several sources. The major sources of information are reports from clinicians and laboratories of newly diagnosed infections, an annual survey of all patients seen for HIV-related treatment or care, and a family of unlinked anonymous surveys which test blood samples taken for other investigations, after they have been irreversibly unlinked from any patient identifiers. All reporting methods are confidential and avoid the use of names.
AIDS is currently defined as an illness characterised by the development of one or more AIDS-indicating conditions. It is diagnosed in people infected with HIV when they develop certain opportunistic infections or malignancies for the first time. The following list relates to diagnosis in adults. Congenital HIV and childhood AIDS has its own separate article.
AIDS-defining conditions in adults
Candidiasis of bronchi, trachea or lungs.Lymphoma, Burkitt's (or equivalent term).
Candidiasis, oesophageal.Lymphoma, immunoblastic (or equivalent term).
Cervical carcinoma, invasive.Lymphoma, primary, of brain.
Coccidioidomycosis, disseminated or extrapulmonary.Mycobacterium avium complex (MAC) or M. kansasii, disseminated or extrapulmonary.
Cryptococcosis, extrapulmonary.Mycobacterium tuberculosis, any site (pulmonary or
extrapulmonary).
Cryptosporidiosis, chronic intestinal (>1 month's duration).Mycobacterium, other species or unidentified species, disseminated or extrapulmonary.
Cytomegalovirus (CMV) disease (other than liver, spleen or nodes).Pneumocystis jirovecii pneumonia.
CMV retinitis (with loss of vision).Pneumonia, recurrent.
Encephalopathy, HIV-related.Progressive multifocal leukoencephalopathy.
Herpes simplex: chronic ulcer(s) (>1 month's duration); or bronchitis, pneumonitis or oesophagitis.Salmonella septicaemia, recurrent.
Histoplasmosis, disseminated or extrapulmonary.Toxoplasmosis of brain.
Isosporiasis, chronic intestinal (>1 month's duration).Wasting syndrome due to HIV.
Kaposi's sarcoma.
This case definition includes 3 new clinical conditions of pulmonary tuberculosis, recurrent pneumonia and invasive cervical carcinoma.
When HIV infection is diagnosed in a routine test, as for blood donation, in pregnancy, or after counselling a person with a lifestyle that puts him or her at risk, there is not usually full AIDS but just infection with HIV. When the disease is suspected, HIV counselling must precede testing. There is a characteristic presentation of the infection that is described in the separate article Primary HIV infection. Once the diagnosis is made, the separate article Managing HIV Positive Individuals in Primary Care becomes relevant. The separate article HIV and Skin Disorders outlines the many dermatological manifestations of the disease.
Awareness of modes of transmission is very important, as the key to tackling this disease lies less in treating it than in preventing its spread. The relative importance of the various means of transmission varies considerably from country to country and even within countries. The following is derived from information on the HPA website and is applicable to the UK.[3]

Sex between men

38% of infections in the UK have occurred through sex between men and this group remains at greatest risk. There has been no evidence in recent years of a decline in the numbers of new infections in this group and over 1,800 new diagnoses of HIV are currently occurring each year.

Despite generally high levels of awareness of the risks for HIV acquisition, in 2008 an estimated 32% of adults aged over 15 years were diagnosed with a CD4 cell count ≤200 per mm3 within three months of diagnosis.[2] The percentage diagnosed with CD4 cell counts ≤350 per mm3 (the threshold at which treatment should be considered according to 2008 British HIV Association guidelines) was 43%.
Estimation of current incidence of HIV is difficult. A newly developed laboratory technique, which identifies recently acquired infections, suggests there has been little change in HIV incidence in men who have sex with men over recent years. If there has been a decrease in transmissibility associated with antiretroviral treatment in those diagnosed it may have been offset by an increase in risky behaviours. London has been the main focus of the HIV epidemic in the UK. Of those infected by sex between men, 55% live in London.

This must be a great disappointment to those who have worked hard to educate this group.

Sex between men and women

Nowadays, the number of new cases of AIDS acquired from heterosexual intercourse is greater than from homosexual activity. However, most of these cases were not acquired in this country. Almost 82% are recorded as having been acquired abroad with around 70% of the total from Africa. In the late 1980s and early 1990s the majority of the African infections were acquired in East Africa but, more recently, the impact of the HIV epidemics in South Eastern Africa has been greater. Infections acquired in Asia and in Latin America/the Caribbean have shown a slight upward trend since the late 1990s but this is modest compared with the contribution of the African epidemic.

In several other European countries there has been much more heterosexual spread from individuals infected through intravenous drug abuse than in the UK. The numbers of acquisitions from high-risk partners diagnosed each year have remained fairly steady and constitute a decreasing percentage of the total of new diagnoses, at around 1.5% of the total of new diagnoses amongst heterosexuals.

With the rise in the numbers of those who acquired their infections heterosexually there has been an increase in the number of women diagnosed. The male:female ratio for all new infections diagnosed in 1985/1986 was approximately 14:1, whereas in 2008 it was about 1.6:1.

It is estimated that around 33% of all HIV infections acquired heterosexually are currently undiagnosed. Many heterosexuals remain undiagnosed until testing is prompted by HIV-related symptoms late in the course of illness. Around two thirds of those with heterosexually acquired infection are being diagnosed late with a CD4 count of less than 350 cells/mm3.

Markers of promiscuity, such as the numbers of new cases of gonorrhoea, are increasing among heterosexuals and this must mean an increased risk of HIV transmission too.

Injecting drug users

The total number of cases of HIV in the UK includes 170 cases from injecting drug use (IDU). IDU has played a smaller part in the HIV epidemic in the UK than it has in many other European countries and the numbers of new diagnoses have been around 100 for the last few years. The age of diagnosis rose throughout the 1990s, suggesting that new diagnoses are being made on an ageing population largely infected in the mid-1980s and that new infections are becoming less frequent. These figures mask geographical variations and, in Eastern Scotland, there was rapid HIV spread through IDU in the early to mid-1980s.

HIV infected injecting drug users are predominantly male as are all drug users. This has meant that the relatively small heterosexual spread from infected drug users has been predominantly to women, with 74% of those reported infected by this route being female.

Behavioural changes among injectors and the prompt introduction of harm reduction measures such as needle exchange programmes from the mid- 1980s probably prevented many other urban areas in the UK from experiencing the localised epidemics on the scale seen in Scotland. In the UK, sharing rates remain higher than in the mid-1990s with almost one in three injectors in the Unlinked Anonymous survey of injecting drug users reporting direct sharing of needles and syringes in the previous 4 weeks. The continuing transmission of hepatitis B and hepatitis C in those aged under 25 shows the potential for further HIV spread among injecting drug users.

Mother to child

There are separate articles on Congenital HIV and its Prevention and Management of HIV in Pregnancy and so this section will be shortened.

HIV prevalence among women giving birth remained highest in London (3.7 per 1,000) and has been stable since 2004. In the rest of England the prevalence has increased five-fold over the past decade but remains relatively low (1.5 per 1,000) in 2008.

By the end of June 2009, 9,874 children (including individuals now aged 16 years or older, but diagnosed before their 16th birthday) had been diagnosed in the UK. Almost all children diagnosed with HIV in the UK in 2008 were reported to have been infected through mother-to-child transmission, and 60% of them were born abroad. Most of the children infected through other routes were infected through blood or blood product treatment in the early 1980s. Since viral inactivation of blood products was introduced in 1985, no transmissions through blood products have been reported in the UK.

About 92% of women with HIV are diagnosed before delivery.They can benefit from interventions which can reduce the risk of mother-to-child transmission to well under 3%. These interventions include: antiretroviral therapy, Caesarean section delivery and avoidance of breast-feeding.

Blood products and blood transfusion

Production of the clotting factor concentrates, mainly to treat patients with haemophilia A and haemophilia B (Christmas disease), involves the pooling of very many donations and a single donation could contaminate a batch of concentrate used to treat many patients. There have been no recorded transmissions of HIV by this route in the UK since the introduction of heat inactivation of concentrates and donor screening in 1985.

Around 1,350 people in the UK have been infected through treatment with blood factor concentrates and all but 13 are male. Two-thirds have died, 31% of them without AIDS having been reported. People with haemophilia may die from liver disease and haemorrhage before the development of an AIDS-defining condition.

Since 1985, all blood donations have been screened for HIV antibody. There have been only two proven incidents of antibody-negative blood infectious for HIV being accepted for transfusion in the UK since then (the donor being in the 'window period' when blood is infectious because of recent HIV infection but too early for antibodies to be reliably detected by the screening antibody test). Most diagnoses from blood transfusions come from areas of the world where screening is unreliable and inconsistent.
Investigations for HIV are described in the separate Human Immunodeficiency Virus (HIV) article. Further investigations for AIDS-defining conditions may be indicated. Media interventions can improve the uptake of testing but this might not be sustained.[4]
The basis of management is described in the separate article on HIV. There may be defining conditions such as Pneumocystis jirovecii pneumonia that will need treatment. Highly active antiretroviral therapy (HAART) has improved the prognosis enormously in terms of duration of survival but premature death is to be expected.

HAART represents the use of at least 3 antiretroviral drugs. New therapies and new regimens are being produced and these should all be assessed by randomised controlled trials. Therefore, as far as possible, everyone with the condition should be included as part of a trial. They will not be expected to take an inert placebo, as effective treatments have been demonstrated and so it is a matter of comparing a new regimen with an existing one, not proving that a new drug is better than nothing. Trials should use standard means of assessment so that meta-analysis may be performed.[5]

Treatments with HAART have shown considerable progress in the past decade with impressive improvements in life expectancy and quality of life.[6] There are still many problems. Although HAART is able to suppress the viral load in the plasma, it fails to eradicate it, and once HAART is initiated, treatment needs to be continued for life. The side-effects of long-term HAART include lipodystrophy, lactic acidosis, insulin resistance, and hyperlipidemia. In addition, patients require high adherence to the therapy to achieve viral suppression and prevent the development of a drug-resistant virus. Modern regimes are less onerous than older ones. They are simpler and involve fewer tablets, whereas it used to be necessary to take 16 to 20 tablets a day.

Some people will wish to use herbal remedies and a Cochrane review was able to find a small number of trials, some of which seemed to have adequate methodology.[7]There was no significant clinical benefit and objective criteria such as CD4 count were unaffected.

There may be some benefits from prophylactic treatment. A Cochrane review found some benefit in treating latent tuberculosis.[8] Another review found only one trial that examined the benefit of prophylactic co-trimoxazole in children. It was from Zambia and the result was positive.[9] The value of prophylaxis against oropharyngeal candidiasis is uncertain, especially in children. There may be some benefit but at a risk of resistance developing and for poorer countries the cheaper options should be examined.[10]
The impact of AIDS in southern Africa has been devastating. The average expectation of life, which had been improving, has started to decline. Some communities have been very hard hit with many deaths and economic hardship related to loss of the workforce of young adults. Children who have not yet reached 10 years old find that one, then both parents become ill, need to be cared for and then die, leaving them to care for themselves and for younger brothers and sisters. This takes them out of school and so they also miss out on education about AIDS. Social care in the community may be hampered by lack of resources due to so many such cases or they may be shunned because of the social stigma. Vertical transmission means that the troubled child may also become ill and die. They are robbed of their childhood. They are robbed of their lives.

The cost of drugs can be prohibitive in such poor economies. If they are not provided by the state, they can be ill afforded by those who need them. The cost of therapy has come down and the price of drugs is being subsidised but the problem of treating so many poor people remains.
The WHO report was quite encouraging with regard to Africa and epidemiology figures above support a slowly improving picture.
The eradication of AIDS is based on prevention rather than cure: this means education and action. Education promotes the use of barrier contraception and advises against risk-taking behaviour eg promiscuity or intravenous drug use. However education can be problematic when a respected body like the Roman Catholic church appears to dispute the risks.[11][12]